Considering the beneficial effects of minocycline in several animal models, it is likely that eukaryotic translation initiation factors, including eIF4AI, would be novel therapeutic targets for certain neurodegenerative and psychiatric diseases. The gene discussed is EIF4A1; the disease is psychiatric disorder.